113 related articles for article (PubMed ID: 18434151)
1. Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.
Deprèle S; Kashemirov BA; Hogan JM; Ebetino FH; Barnett BL; Evdokimov A; McKenna CE
Bioorg Med Chem Lett; 2008 May; 18(9):2878-82. PubMed ID: 18434151
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
Marma MS; Xia Z; Stewart C; Coxon F; Dunford JE; Baron R; Kashemirov BA; Ebetino FH; Triffitt JT; Russell RG; McKenna CE
J Med Chem; 2007 Nov; 50(24):5967-75. PubMed ID: 17975902
[TBL] [Abstract][Full Text] [Related]
3. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.
De Schutter JW; Zaretsky S; Welbourn S; Pause A; Tsantrizos YS
Bioorg Med Chem Lett; 2010 Oct; 20(19):5781-6. PubMed ID: 20801032
[TBL] [Abstract][Full Text] [Related]
4. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors.
Błażewska KM; Ni F; Haiges R; Kashemirov BA; Coxon FP; Stewart CA; Baron R; Rogers MJ; Seabra MC; Ebetino FH; McKenna CE
Eur J Med Chem; 2011 Oct; 46(10):4820-6. PubMed ID: 21889236
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
McKenna CE; Kashemirov BA; Błazewska KM; Mallard-Favier I; Stewart CA; Rojas J; Lundy MW; Ebetino FH; Baron RA; Dunford JE; Kirsten ML; Seabra MC; Bala JL; Marma MS; Rogers MJ; Coxon FP
J Med Chem; 2010 May; 53(9):3454-64. PubMed ID: 20394422
[TBL] [Abstract][Full Text] [Related]
7. NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.
Mukherjee S; Song Y; Oldfield E
J Am Chem Soc; 2008 Jan; 130(4):1264-73. PubMed ID: 18173269
[TBL] [Abstract][Full Text] [Related]
8. Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity.
No JH; de Macedo Dossin F; Zhang Y; Liu YL; Zhu W; Feng X; Yoo JA; Lee E; Wang K; Hui R; Freitas-Junior LH; Oldfield E
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4058-63. PubMed ID: 22392982
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of a series of aromatic bisphosphonates.
Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326
[TBL] [Abstract][Full Text] [Related]
10. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
[TBL] [Abstract][Full Text] [Related]
11. Novel multisubstrate inhibitors of mammalian purine nucleoside phosphorylase.
Toms AV; Wang W; Li Y; Ganem B; Ealick SE
Acta Crystallogr D Biol Crystallogr; 2005 Nov; 61(Pt 11):1449-58. PubMed ID: 16239721
[TBL] [Abstract][Full Text] [Related]
12. Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc.
Huang CY; Stauffer TM; Strickland CL; Reader JC; Huang H; Li G; Cooper AB; Doll RJ; Ganguly AK; Baldwin JJ; Rokosz LL
Bioorg Med Chem Lett; 2006 Feb; 16(3):507-11. PubMed ID: 16289818
[TBL] [Abstract][Full Text] [Related]
13. Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.
Nishiguchi T; Akiyoshi T; Anami S; Nakabayashi T; Matsuyama K; Matzno S
J Pharm Pharmacol; 2009 Jun; 61(6):781-8. PubMed ID: 19505369
[TBL] [Abstract][Full Text] [Related]
14. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic insights into protonation state as a critical factor in hFPPS enzyme inhibition.
Fernández D; Ortega-Castro J; Mariño L; Perelló J; Frau J
J Comput Aided Mol Des; 2015 Jul; 29(7):667-80. PubMed ID: 26081258
[TBL] [Abstract][Full Text] [Related]
16. A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues.
Margiotta N; Capitelli F; Ostuni R; Natile G
J Inorg Biochem; 2008 Dec; 102(12):2078-86. PubMed ID: 18760482
[TBL] [Abstract][Full Text] [Related]
17. Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
Hounslow AM; Carran J; Brown RJ; Rejman D; Blackburn GM; Watts DJ
J Med Chem; 2008 Jul; 51(14):4170-8. PubMed ID: 18590315
[TBL] [Abstract][Full Text] [Related]
18. Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls.
De Schutter JW; Shaw J; Lin YS; Tsantrizos YS
Bioorg Med Chem; 2012 Sep; 20(18):5583-91. PubMed ID: 22884353
[TBL] [Abstract][Full Text] [Related]
19. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RG; Oppermann U
Proc Natl Acad Sci U S A; 2006 May; 103(20):7829-34. PubMed ID: 16684881
[TBL] [Abstract][Full Text] [Related]
20. Crystallization and preliminary neutron diffraction experiment of human farnesyl pyrophosphate synthase complexed with risedronate.
Yokoyama T; Ostermann A; Mizuguchi M; Niimura N; Schrader TE; Tanaka I
Acta Crystallogr F Struct Biol Commun; 2014 Apr; 70(Pt 4):470-2. PubMed ID: 24699741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
